MedTrace Logo

Multi-"Omics" Research of Danhong Injection to Treat Acute Ischemic Stroke

NCT02176395 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 46

Last updated 2020-07-15

No results posted yet for this study

Summary

The purpose of this study is to explore the pharmacological mechanism of Danhong injection in the treatment of acute ischemic stroke.

Conditions

  • Acute Stroke

Interventions

DRUG

Danhong injection

40ml Danhong injection added into 250ml 0.9% saline by an independent research nurse, sealed with brown bag in order to make the investigators and patients blinded, using brown infusion tube for infusion

PROCEDURE

Standard medical care

Standard medical care is in accordance with China Guideline for the diagnosis and treatment of acute ischemic stroke (2010), including medical care for vital signs, control of temperature, blood pressure and glucose, improving cerebral blood circulation, antiplatelet treatment and nutritional supportive care.

DRUG

placebo

0.9% saline added into 250ml 0.9% saline by an independent research nurse, sealed with brown bag in order to make the investigators and patients blinded, using brown infusion tube for infusion

Sponsors & Collaborators

  • China Food and Drug Administration

    collaborator OTHER_GOV

  • China Academy of Chinese Medical Sciences

    lead OTHER

Principal Investigators

  • Wang Zhong, Professor · Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences

  • Zhao Xingquan, Professor · Beijing Tiantan Hospital

  • Wang Yongyan, Professor · Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences

  • Jiang Zhilin, Professor · 202 Military Hospital of China

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-06-30
Primary Completion
2019-03-31
Completion
2020-07-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02176395 on ClinicalTrials.gov